Completed PHASE2 INTERVENTIONAL NCT00003264

Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer

Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck

Sponsor: Fox Chase Cancer Center

Conditions Head and Neck Cancer

Interventions cisplatin gemcitabine hydrochloride

Updated 6 times since 2017 Last updated: Apr 16, 2013 Started: Oct 31, 1997 Primary completion: Feb 28, 2002 Completion: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Head and Neck Cancer and is currently completed. Fox Chase Cancer Center leads this study, which shows 6 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fox Chase Cancer Center
National Cancer Institute (NCI)

Data source: Fox Chase Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bethlehem, United States , Drexel Hill, United States , Flemington, United States , Harrisburg, United States , Langhorne, United States , Lansdale, United States , Mount Holly, United States , Paoli, United States , Philadelphia, United States , Reading, United States and 2 more locations